Catapult Healthcare: Traveling Nurse Agency Recruitment Is on the Rise (Part 2 of 2)

In Part 2 of this exciting 2-Part series, podcast host Gabrielle Bejarano sat down with Paul Shoe, RN, Suzanne Raymond, National Recruiter at Catapult Healthcare, and Shannon Kanakaole, Recruiting Operations Manager at Catapult Healthcare, to talk about how nurses and agencies can effectively work together and tackle challenges that arise while on contract.

Shoe, a registered nurse contracted through Catapult Healthcare, says that his experience with being hired through an agency has been smooth and he’s now preparing to extend his current contract. However, Shoe noted that traveling nurse contracts may have terms that those new to the industry may not understand. For example, many contracts include a floating clause.

Floating allows nurses to work on different floors and specialties to support hospital needs at any given time. Shoe noted that sometimes “people really get upset when they have to go to another place out of their comfort zone.” Recruiters would be prudent to discuss floating options with potential candidates, and candidates not comfortable with floating need to make sure their recruiter knows.

It’s important for nurses to “try to have communication as much as possible with your recruiter and the facility if need be,” recommends Shoe, RN. Travel “nursing can be very fluid… you’ve gotta be willing to roll with it,” said Shoe.

Suzanne Raymond, Recruiter with Catapult Healthcare, finds success with floating terms “if I tell people that upfront,” and they know what to expect. Of course, maintaining a comfort level with their skills and experience is essential. And if a nurse finds themselves outside of their comfort zone, they should get in touch with their recruiter right away. “We’ll do what we can from our side to advocate for our people,” said Raymond.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More